Ozanimod is a medicine used to treat multiple sclerosis and ulcerative colitis. It is a capsule taken by mouth once a day. It works by keeping some immune cells in the lymph nodes so they can't cause swelling in the brain or the gut.
Every report comes from a Lived member, sent anonymously.
Have you tried Zeposia (Ozanimod) for MS (Multiple Sclerosis)?
Ozanimod, sold as Zeposia, is a once-daily capsule that keeps certain immune cells from reaching the tissues they inflame. It is approved for adults with two quite different conditions. In multiple sclerosis (MS), it treats relapsing forms of the disease: clinically isolated syndrome (a first episode of MS-like symptoms), relapsing-remitting MS, and secondary progressive MS that is still showing active inflammation. It is not approved for primary progressive MS. It is also approved for adults with moderately to severely active ulcerative colitis, an inflammatory bowel disease that causes ulcers in the lining of the colon and rectum, bloody diarrhea and urgency. In its trials, people had not done well enough on, or could not tolerate, at least one earlier treatment such as mesalamine, steroids or a biologic. Some people choose it because it is taken by mouth rather than by injection or infusion. Ozanimod belongs to a group called sphingosine 1-phosphate (S1P) receptor modulators. Other medicines in this group are used for MS or ulcerative colitis, but their doses, monitoring and approved uses differ, so they are not interchangeable.
Lymphocytes are white blood cells that drive the inflammation in both MS and ulcerative colitis. They normally travel out of the lymph nodes, through the bloodstream and into tissues. To leave a lymph node, they rely on a signal from a molecule called S1P. Ozanimod blocks the receptor that reads this signal, so many lymphocytes stay inside the lymph nodes. The number circulating in the blood drops to roughly half of its usual level. Fewer of these cells reach the brain and spinal cord in MS, or the gut lining in ulcerative colitis, which is thought to explain the benefit, although the exact mechanism is not fully known. The cells are held back rather than destroyed, so counts recover after the medicine is stopped, usually within about one to three months.
Ozanimod starts with a 7-day starter pack: a low dose on days 1 to 4, a higher dose on days 5 to 7, and the full daily dose of 0.92 mg from day 8. This step-up limits a temporary slowing of the heart rate that can happen when the medicine is first started. Capsules are swallowed whole, with or without food. People with mild or moderate liver problems take the full-strength capsule every other day instead of daily, and it is not recommended with severe liver disease. Missing doses matters most at the start. If a dose is missed in the first 2 weeks, the starter pack has to be repeated from the beginning, so call the prescriber for a plan. After the first 2 weeks, a missed dose is simply skipped and the usual schedule continues. Several checks come before the first dose: an electrocardiogram (ECG, a recording of the heart's rhythm), a blood count, liver tests, an eye exam that looks at the retina, and a skin check. People with no confirmed history of chickenpox or chickenpox vaccination are tested for immunity and vaccinated first if needed, with treatment then delayed about 4 weeks. Any other needed live vaccines are also given at least a month before starting.
In clinical trials, the most common side effects were colds and other upper respiratory infections, raised liver enzymes on blood tests, headache, urinary tract infections, back pain, higher blood pressure and dizziness when standing up. Many people notice little day to day, which is why routine blood tests and blood pressure checks matter. Because fewer immune cells are circulating, infections can be more frequent and, rarely, serious or life-threatening. Shingles and other herpes infections are more common. Tell the care team about fever, chills or other signs of infection, during treatment and for 3 months after the last dose. A few serious effects are rare but important to recognize. Contact the care team promptly about the first two below; the third needs immediate medical attention: Unexplained nausea, vomiting, stomach pain, unusual tiredness, loss of appetite, yellowing of the skin or eyes, or dark urine, which can signal liver injury. Severe liver injury, including liver failure needing a transplant, has been reported. Weakness on one side of the body that worsens over days or weeks, clumsiness, vision changes, or new confusion or memory problems. These can be signs of PML (progressive multifocal leukoencephalopathy), a rare but serious brain infection, mostly seen after 18 months or more of this type of medicine. A sudden severe headache, confusion, vision disturbance or a seizure. These need immediate medical attention because they can signal a rare brain swelling disorder. Blurred vision, shadows or other changes in eyesight can come from macular edema, swelling in the center of the retina, which is more likely in people with diabetes or a history of uveitis (inflammation inside the eye). New or worsening shortness of breath should also be reported, since small declines in lung function have been measured.
Ozanimod is not used by people who in the past 6 months had a heart attack, stroke, mini-stroke (transient ischemic attack), unstable angina, heart failure needing hospital care, or severe heart failure. It is also not used with certain heart rhythm blocks unless a pacemaker is in place, or with severe sleep apnea that is not being treated. Anyone with other heart conditions may need a cardiologist's advice first. It must not be combined with monoamine oxidase (MAO) inhibitors, a group that includes the antidepressant phenelzine, the Parkinson's medicine selegiline and the antibiotic linezolid; at least 14 days should pass after stopping ozanimod before starting one. Some heart medicines add to the slowing of heart rate or rhythm that ozanimod can cause at the start. For that reason, starting ozanimod is generally avoided in people taking both a beta blocker (a common heart and blood pressure medicine) and a heart-rate-lowering calcium channel blocker such as verapamil or diltiazem. The same caution applies to certain heart rhythm drugs and other medicines that prolong the QT interval (a measure of how long the heart takes to reset between beats) on an ECG. In these situations a cardiologist should weigh in. Gemfibrozil, a cholesterol medicine, raises ozanimod levels and is not recommended, while the antibiotic rifampin lowers them and should be avoided. Other immune-suppressing treatments add to infection risk, so the timing of a switch from a previous MS or colitis medicine needs planning. Starting after alemtuzumab (Lemtrada) is not recommended: it is an MS infusion that destroys immune cells, and their counts can stay low for a year or more. Live vaccines (vaccines made with a weakened form of the germ) should be avoided during treatment and for 3 months after stopping, and other vaccines may work less well. Ozanimod may harm a developing baby, based on animal studies. People who could become pregnant should use effective birth control during treatment and for 3 months after the last dose, and should tell the prescriber right away about a pregnancy or plans for one. Medicines in this group also raise the risk of skin cancers, including melanoma, so skin checks, sun protection and prompt review of new or changing spots are part of routine care.
In ulcerative colitis, less bleeding and fewer bathroom trips were seen as early as 2 weeks into treatment, though full improvement can take longer. In the main trial, about 18% of people were in remission after 10 weeks, compared with 6% on a placebo. Among those who had responded by then, 37% were in remission after a year on ozanimod, compared with 19% who switched to placebo. Results were lower in people who had already tried biologics called tumor necrosis factor (TNF) blockers. In MS, the goal is fewer relapses and fewer new areas of inflammation on MRI scans, not a change you feel from day to day. In two large trials, people taking ozanimod had 38% to 48% fewer relapses than those using weekly injections of interferon beta-1a, an older MS medicine, though disability progression over 2 years was similar. Ozanimod does not reverse damage already done. Treatment is ongoing, with blood pressure checks, periodic liver tests, eye exams (especially with any vision change) and skin checks. The effects on the immune system take about 3 months to wear off after stopping. In MS, stopping can rarely be followed by a severe return of disease activity, so any change should be planned with the neurologist, and worsening symptoms after stopping should be reported.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Zeposia (Ozanimod), what you've noticed, or ask the community a question.